Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status

Annals of Oncology

Volumn 17, Issue 5, 2006, Pages 818-826

  Dowsett, Mitch ^a   Houghton, J ^b   Iden, C ^b   Salter, J ^a   Farndon, J ^c   A'Hern, R ^d   Sainsbury, R ^b   Baum, M ^e  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c BRISTOL ROYAL INFIRMARY   (United Kingdom)

^d INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^e Portland Hospital   (United Kingdom)

Author keywords

Early breast cancer; EGFR; ER; HER2; PgR; Tamoxifen

Indexed keywords

CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TAMOXIFEN CITRATE;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

EID: 33646198056     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdl016     Document Type: Article

References (42)

1. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: An overview of the randomised trials. Lancet 1998; 351: 1451-1467.
2. Fisher B, Constantino JP, Wickerham DL et al. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1. J Natl Cancer Inst 1998; 90: 1371-1388.
3. Winer EP, Hudis C, Burstein HJ et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: Status report 2004. J Clin Oncol 2005; 23: 619-629.
4. McGuire WL. Steroid hormone receptors in breast cancer treatment strategy. Recent Prog Hormone Res 1980; 36: 135-156.
5. Harvey JM, Clark GM, Osborne CK, Allred DC. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999; 17: 1471-1481.
6. Horwitz KB, McGuire WL. Oestrogen control of progesterone receptor in human breast cancer: Correlation with nuclear processing of oestrogen receptor. J Biol Chem 1978; 253: 2223-2228.
7. Alexieva-Figusch J, Van Putten WLJ, Blankenstein MA et al. The prognostic value and relationships of patient characteristics, estrogen and progestin receptors and site of relapse in primary breast cancer. Cancer 1988; 61: 758-768.
8. Harris AL, Nicholson S, Sainsbury JRC et al. Epidermal growth factor receptors in breast cancer: Association with early relapse and death, poor response to hormones and interaction with neu. J Steroid Biochem 1989; 34: 123-133.
9. Wright C, Nicholson S, Angus B et al. Relationship between erb-B2 protein product expression and response to endocrine therapy in advanced breast cancer. Br J Cancer 1992; 65: 118-121.
10. Nolvadex Adjuvant Trial Organization. Controlled trial of tamoxifen as single adjuvant agent in management of early breast cancer. Lancet 1985; i: 836-839.
11. Nolvadex Adjuvant Trial Organisation. Controlled trial of tamoxifen as single adjuvant agent in management of early breast cancer. Analysis at Eight Years. Brit J Cancer 1988; 57: 608-611.
12. CRC Adjuvant Breast Trial Working Party. Cyclophosphamide and tamoxifen as adjuvant therapies in the management of breast cancer. Br J Cancer 1988; 57: 604-607.
13. Saccani-Jotti G, Johnston SRD, Salter J et al. Comparison of a new immunohistochemical assay for oestrogen receptor in paraffin wax embedded breast carcinomas tissue with quantitative enzyme immunoassay. J Clin Path 1994; 47: 900-905.
14. Detre S, Salter J, Barnes DM et al. Time-related effects of oestrogen withdrawal on proliferation and cell death-related events in MCF7 xenografts. Int J Cancer 1999; 81: 309-313.
15. Styles JM, Harrison S, Gusterson BA, Dean CJ. Rat monoclonal antibodies to the external domain of the product of the c-erbB2 proto-oncogene. Int J Cancer 1990; 45: 320-324.
16. Newby JC, A'Herne RA, Leek RD et al. Immunohistochemical assay for epidermal growth factor receptor on paraffin-embedded sections: validation against ligand binding assay and clinical relevance in breast cancer. Brit J Cancer 1995; 71: 1237-1242.
17. Early Breast Cancer Trialist's Group. Statistical Methods. In: Treatment of Early Breast Cancer. Volume 1. Worldwide Evidence 1985-1990. Oxford University Press, Oxford 1990; 12-18.
18. Newby JC, Johnston SRD, Smith IE et al. Expression of epidermal growth factor receptor and c-erbB2 during the development of tamoxifen resistance in human breast cancer. Clin Cancer Res 1997; 3: 1643-1651.
19. Dowsett M, Richner J. Effects of cytotoxic chemotherapy on ovarian and adrenal steoridogenesis in premenopausal breast cancer patients. Oncology 1991; 48: 215-220.
20. Howell A. Adjuvant aromatase inhibitors for breast cancer. Lancet 2005; 366: 431-433.
21. Sainsbury JRC, Farndon JR, Sherbet GV et al. Epidermal-growth-factor receptors and oestrogen receptors in human breast cancer. Lancet 1985; i: 364-366.
22. Press MF, Hung G, Godolphin W, Slamon DJ et al. Sensitivity of HER-2/neu antibodies in archival tissue samples: Potential source of error in immunohistochemical studies of oncogene expression. Cancer Res 1994; 54: 2771-2777.
23. Tovey S, Dunne B, Witton CJ et al. Can molecular markers predict when to implement treatment with aromatase inhibitors in invasive breast cancer? Clin Cancer Res. 2005; 11: 4835-4842.
24. Arpino G, Weiss H, Lee A et al. Estrogen receptor positive (ER+), progesterone receptor (PgR-) breast cancer: New insights into molecular mechanisms and clinical implications. Breast Cancer Res Treat 2004; 88: S21.
25. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet. 2005; 365: 1687-1717.
26. McGuire WL, Chamness GC, Fuqua SAW. Estrogen receptor variants in clinical breast cancer. Endocrinol 1991; 5; 1571-1577.
27. Daffada AAI, Johnston SRD, Smith IE et al. Exon 5-deletion variant oestrogen receptor mRNA expression in relation to tamoxifen resistance and PgR/pS2 status in human breast cancer. Cancer Res 1995; 55: 288-293.
28. Rowlands MG, Parr IB, McGague R et al. Variation of inhibition of calmodulin dependent cyclic AMP phosphodiesterase amongst analogues of tamoxifen; correlations with cytoxicity. Biochem Pharmacol 1990; 49: 283-289.
29. Bignon E, Ogita K, Kishimoto A, et al. Modes of inhibition by protein kinase C by triphenylacrylonitrile antiestrogens. Biochem Biophys Res Commun 1989; 163: 1377-1383.
30. Ho GH, Ji CY, Phang BH et al. Tamoxifen alters levels of insulin-like growth factors and binding proteins in postmenopausal breast cancer patients: A prospective paired short study. Ann Surg Oncol 1998; 5: 361-367.
31. Butta A, MacLennan K, Flanders K et al. Evidence for the induction of transforming growth factor β1 in human breast cancer in vivo following tamoxifen treatment. Cancer Res 1992; 52: 4261-4264.
32. Bardou VJ, Arpino G, Elledge RM et al. Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J Clin Oncol. 2003; 21: 1973-1979.
33. Dowsett M, Cuzick J, Wale C et al. Retrospective analysis of time to recurrence in the ATAC trail according to hormone receptor status: An hypothesis generating study. J Clin Oncol 2005; 23: 7512-7517.
34. Berns EMJJ, Foekens JA, van Staveren IL et al. Oncogene amplification and prognosis in breast cancer: Relationship with systematic treatment. Gene 1995; 159: 11-18.
35. Bianco AR, De Laurentis M, Carlomagno C et al. 20 year update of the Naples GUN trial of adjuvant breast cancer therapy: Evidence of interaction between c-erbB2 expression and tamoxifen efficacy. Proc Am Soc Clin Oncol 1998; 17: 97A.
36. Leitzel K, Teramoto Y, Konrad K et al. Elevated serum c-erbB2 antigen levels and decreased response to hormone therapy of breast cancer. J Clin Oncol 1995; 13: 1129-1135.
37. Nicholson RI, McClelland RA, Finlay P et al. Relationship between EGF-R, c-erbB2 protein expression and Ki67 immunostaining in breast cancer and hormone sensitivity. Eur J Cancer 1993; 29A: 1018-1023.
38. Plunkett TA, Houston SJ, Rubens RD et al. C-erbB2 is a marker of resistance to endocrine therapy in advanced breast cancer. Proc Am Soc Clin Oncol 1998; 17: 103a.
39. Wright C, Nicholson S, Angus B et al. Relationship between c-erbB2 protein product expression and response to endocrine therapy in advanced breast cancer. Br J Cancer 1992; 65: 118-121.
40. Yamauchi H, O'Neill A, Gelman R et al. Prediction of response to antiestrogen therapy in advanced breast cancer patients by re-treatment circulating levels of extracellular domain of the HER-2/c-neu protein. J Clin Oncol 1997; 15: 2528-2525.
41. Kaufman M, Graf E, Jonat W et al. Tamoxifen versus control after adjuvant, riskadapted chemotherapy in postmenopausal, receptor-negative patients with breast cancer (GABG-IV D-93) - The German Adjuvant Breast Group. J Clin Oncol 2005; 23: 7842-7848.
42. Goldhirsch A, Glick JH, Gelber RD et al. Meeting highlights: International expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 2005; 16: 1669-1583.